Screener
ImmunityBio, Inc. IBRX Q2 2026 earnings
Reported August 4, 2026 · Before market open
Revenue$51.2MBeat by $1.5M
EPS-$0.22Miss by $0.14
Revenue estimate$49.7M
EPS estimate-$0.08
“Our record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKTIVA and disciplined commercial execution. At the same time, we continue to invest in expanding ANKTIVA's global commercial footprint while advancing a focused late-stage clinical pipeline that we believe will create additional opportunities across multiple oncology indications. With $357.4 million in cash and cash equivalents, and marketable securities, we are well-positioned to support both our commercial and clinical priorities.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$59.2M
EPS estimate-$0.08
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did ImmunityBio, Inc. report Q2 2026 earnings?
- ImmunityBio, Inc. (IBRX) reported Q2 2026 earnings on August 4, 2026 before market open.
- What were ImmunityBio, Inc.'s Q2 2026 revenue and EPS?
- ImmunityBio, Inc. reported revenue of $51.2M and eps of $-0.22 for Q2 2026.
- Did ImmunityBio, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $49.7M by $1.5M. EPS missed the consensus estimate of $-0.08 by $0.14.
- How did ImmunityBio, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 93.9% from $26.4M a year earlier and eps declined 120.0% from $-0.10.
- Where can I find ImmunityBio, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001326110-26-000077) and the 10-Q periodic report (0001326110-26-000079) directly on SEC EDGAR. The filing index links above go to sec.gov.
